This past week saw four IPOs raise over $400 million, making it the year's busiest week by deal count. The first venture capital tech IPO, Acacia Communications, had the year's best first-day pop (+35%), while CD&R's landscaping LBO, SiteOne, had the year's second-best debut (+27%). We attribute their success to strong business fundamentals, demonstrating growth and...read more
Oncobiologics, which is developing biosimilars of blockbuster drugs Humira and Avastin, raised $35 million by offering 5.8 million units at $6.
Oncobiologics plans to list on the Nasdaq under the symbol ONS. Jefferies and Barclays acted as lead managers on the deal....read more
Oncobiologics, which is developing biosimilars of blockbuster drugs Humira and Avastin, lowered the proposed deal size for its upcoming IPO on Wednesday. The Cranbury, NJ-based company now plans to raise $35 million by offering 5.8 million shares at a price of $6. Insiders intend to purchase $20 million worth of shares in the offering. In addition, Sabby Healthcare Master Fund...read more
The IPO market is scheduled to have its busiest week yet. As many as six companies could go public this week and raise a combined $555 million, including the first venture capital-backed tech IPO of the year. Optical network IPO helps VC tech see the light ...read more
US IPO Weekly Recap: Tech and landscaping IPOs secure top two first-day pops of 2016
This past week saw four IPOs raise over $400 million, making it the year's busiest week by deal count. The first venture capital tech IPO, Acacia Communications, had the year's best first-day pop (+35%), while CD&R's landscaping LBO, SiteOne, had the year's second-best debut (+27%). We attribute their success to strong business fundamentals, demonstrating growth and...read more
Oncobiologics prices IPO at $6, as expected
Oncobiologics, which is developing biosimilars of blockbuster drugs Humira and Avastin, raised $35 million by offering 5.8 million units at $6. Oncobiologics plans to list on the Nasdaq under the symbol ONS. Jefferies and Barclays acted as lead managers on the deal....read more
Late-stage biosimilars biotech Oncobiologics slashes proposed IPO deal size and adds warrants
Oncobiologics, which is developing biosimilars of blockbuster drugs Humira and Avastin, lowered the proposed deal size for its upcoming IPO on Wednesday. The Cranbury, NJ-based company now plans to raise $35 million by offering 5.8 million shares at a price of $6. Insiders intend to purchase $20 million worth of shares in the offering. In addition, Sabby Healthcare Master Fund...read more
Week Ahead: VC tech reignites IPO market with six deals
The IPO market is scheduled to have its busiest week yet. As many as six companies could go public this week and raise a combined $555 million, including the first venture capital-backed tech IPO of the year. Optical network IPO helps VC tech see the light ...read more